FDA has expanded the indication for Sprycel (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
